Pulse Biosciences Inc
$ 20.51
4.40%
16 Apr - close price
- Market Cap 1,394,456,000 USD
- Current Price $ 20.51
- High / Low $ 20.69 / 19.75
- Stock P/E N/A
- Book Value 1.19
- EPS -1.08
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.74 %
- 52 Week High 26.30
- 52 Week Low 12.56
About
Pulse Biosciences, Inc. is a bioelectrical medicine startup. The company is headquartered in Hayward, California.
Analyst Target Price
$30.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-20 | 2025-10-29 | 2025-08-12 | 2025-05-05 | 2025-03-26 | 2024-10-30 | 2024-08-19 | 2024-05-07 | 2024-03-28 | 2023-11-13 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.18 | -0.29 | -0.28 | -0.2502 | -0.3124 | -0.2076 | -0.1991 | -0.1837 | -0.2167 | -0.19 | -0.22 | -0.26 |
| Estimated EPS | -0.21 | -0.31 | -0.26 | None | -0.24 | -0.24 | -0.2 | -0.24 | -0.24 | -0.22 | -0.22 | -0.22 |
| Surprise | 0.03 | 0.02 | -0.02 | 0 | -0.0724 | 0.0324 | 0.0009 | 0.0563 | 0.0233 | 0.03 | 0 | -0.04 |
| Surprise Percentage | 14.2857% | 6.4516% | -7.6923% | None% | -30.1667% | 13.5% | 0.45% | 23.4583% | 9.7083% | 13.6364% | 0% | -18.1818% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.32 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLSE
2026-04-16 16:39:32
Pulse Biosciences (PLSE) is conducting the PRECISE-BTN clinical study to evaluate its nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. This interventional study aims to confirm early human data on symptom relief and quality of life improvement after device-based ablation, offering a minimally invasive alternative to surgery. Positive results could boost PLSE's position in the thyroid care market.
2026-04-16 12:39:32
Pulse Biosciences (PLSE) has released an updated investor presentation detailing its ongoing cardiac and soft tissue programs. The deck provides new information on the pivotal clinical study for its nsPFA Cardiac Catheter, introduces the next-generation nPulse cardiac catheter, and outlines corporate goals for 2026 in electrophysiology, cardiac surgery, and soft tissue ablation. This presentation is intended for meetings with investors and analysts and contains forward-looking statements.
2026-04-15 23:28:00
Pulse Biosciences Inc (PLSE) is exhibiting a mid-channel oscillation pattern with an exceptional 84.0:1 risk-reward setup, targeting a 22.8% gain against 0.3% risk. AI models have generated three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles. The stock shows positive near-term sentiment within a long-term strength context, despite mid-term weakness.
2026-04-13 19:41:46
Pulse Biosciences has begun enrolling patients in its NANOPULSE-AF IDE pivotal study, evaluating its Nano-Pulse Stimulation (NPS) technology for atrial fibrillation treatment. This marks a significant step towards regulatory approval and commercialization, targeting the large and growing AF ablation market with a technology designed to minimize collateral tissue damage. The company's shares gained 36% year-to-date, contrasting with a 6.5% drop post-announcement, as investors eye clinical progress and regulatory outcomes.
2026-04-13 10:39:34
Pulse Biosciences has strengthened its leadership team with new appointments aimed at accelerating the commercialization of its nPulse Cardiac Catheter Ablation System for atrial fibrillation. These changes align with the first patient enrollments in the pivotal NANOPULSE-AF study, critical for validating the technology. While the leadership moves support execution, investors are advised to consider the company's high cash burn and minimal revenue against its projected significant revenue and earnings growth.
2026-04-10 18:05:41
Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer, giving her oversight of efforts to bring their nPulse Cardiac Catheter, a pulsed field ablation (PFA) device for treating atrial fibrillation, to market. Teplitsky's experience from Abbott and Zimmer Biomet is expected to be instrumental in accelerating the company's strategic priorities, including a pivotal U.S. and European trial for the device. This appointment follows Pulse Biosciences' decision to focus most of its R&D budget on the PFA device after promising first-in-human data.
